3-(2-羟乙基)-2-甲基喹唑啉-4-酮 | 10376-59-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 3-(2-羟乙基)-2-甲基喹唑啉-4-酮
• 英文名称: 3-(2-hydroxyethyl)-2-methylquinazolin-4(3H)-one
• 英文别名: 4(3H)-Quinazolinone, 3-(2-hydroxyethyl)-2-methyl-；3-(2-hydroxyethyl)-2-methylquinazolin-4-one
• CAS: 10376-59-7
• 化学式: C₁₁H₁₂N₂O₂
• mdl: MFCD00680278
• 分子量: 204.228
• InChiKey: JRXGAWVXJUVHTD-UHFFFAOYSA-N

物化性质

• 熔点：
  134 °C
• 沸点：
  388.4±44.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(2-羟乙基)-2-甲基喹唑啉-4-酮 在 甲基磺酰氯 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以88.8%的产率得到2-methyl-3-(2-chloroethyl)-4(3H)-quinazolinone
  参考文献：
  名称：

  [EN] FIBRATE COMPOUNDS HAVING PPAR AGONIST ACTIVITY
  [FR] COMPOSES DE FIBRATE POSSEDANT UNE ACTIVITE AGONISTE PPAR

  摘要：

  公开号：

  WO2006029075A3
• 作为产物：
  描述：

  2-(2-甲基-4-氧代-3,4-二氢-3-喹唑啉基)乙酸乙酯 在 甲醇 、 水 、 sodium carbonate 作用下， 反应 4.0h， 以96.4%的产率得到3-(2-羟乙基)-2-甲基喹唑啉-4-酮
  参考文献：
  名称：

  [EN] FIBRATE COMPOUNDS HAVING PPAR AGONIST ACTIVITY
  [FR] COMPOSES DE FIBRATE POSSEDANT UNE ACTIVITE AGONISTE PPAR

  摘要：

  公开号：

  WO2006029075A3

文献信息

• Synthesis of quinazoin-4-ones through an acid ion exchange resin mediated cascade reaction
  作者：Huiyong Yang、Jun Xu、Yilan Zhang、Lei He、Pengfei Zhang、Wanmei Li

  DOI：10.1039/d0ob00881h

  日期：——

  cascade reaction of N-(2-(4,5-dihydrooxazol-2-yl)phenyl)benzamide in the presence of an acid ion exchange resin is described. In this reaction, a range of substrates bearing various substituent groups are well compatible. This work provides a green and atom-economical alternative approach for the synthesis of quinazolin-4-ones in good yields.

  描述了在酸性离子交换树脂存在下N-（2-（4,5-二氢恶唑-2-基）苯基）苯甲酰胺的有趣的级联反应。在该反应中，具有各种取代基的一系列底物是良好相容的。这项工作提供了绿色和原子经济的替代方法，以高收率合成喹唑啉-4-酮。
• Treatment of platelet derived growth factor related disorders such as cancers
  申请人：University of California

  公开号：US06331555B1

  公开（公告）日：2001-12-18

  The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.

  本发明涉及能够抑制血小板源性生长因子受体（PDGF-R）活性的化合物，最好这些化合物还能抑制PDGF-R超家族的其他成员的活性，并且对PDGF-R超家族的成员具有选择性。PDGF-R超家族包括PDGF-R和PDGF-R相关激酶Flt和KDR。这些特色化合物在细胞培养中对降低PDGF-R活性以及最好地对一种或多种PDGF-R相关激酶具有活性。下面描述了一种特色化合物A10（见图1a）及其抑制体内肿瘤细胞生长的能力。利用本申请作为指南，可以获得其他能够抑制PDGF-R、最好是Flt和/或KDR的化合物。这些化合物最好用于治疗患有由不适当PDGF-R活性特征的细胞增殖紊乱症状的患者。
• Treatment of platelet derived growth factor related disorders such as
  申请人：Sugen Inc.

  公开号：US05990141A1

  公开（公告）日：1999-11-23

  The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.

  本发明涉及一类可以抑制血小板源性生长因子受体（PDGF-R）活性的化合物，最好这些化合物还可以抑制PDGF-R超家族的其他成员的活性，并且对PDGF-R超家族的成员具有选择性。PDGF-R超家族包括PDGF-R和PDGF-R相关激酶Flt和KDR。这些特色化合物在细胞培养中对降低PDGF-R活性以及最好是一个或多个PDGF-R相关激酶的活性方面是活跃的。下面描述了一个特色化合物A10（见图1a）及其在体内抑制肿瘤细胞生长的能力。通过本申请作为指南，可以获得其他能够抑制PDGF-R，最好是Flt和/或KDR的化合物。这些化合物最好用于治疗患有细胞增殖异常的患者，其特征是PDGF-R活性异常。
• Nitrogen bridgehead compounds. Part<b>85</b>. Synthesis and reactivity of 3,4-dihydro-1<i>H</i>,6<i>H</i>[1,4]oxazino[3,4-<i>b</i>]quinazolin-6-ones
  作者：István Hermecz、Ildikó Szilágyi、László Orfi、József Kökösi、György Szász

  DOI：10.1002/jhet.5570300539

  日期：1993.10

  3,4-Dihydro-1H,6H-[1,4]oxazino[3,4-b]quinazolin-6-one 3 and its 1-methyl and 1-hydroxy derivatives 8 and 13 were prepared by different routes. The active methylene group of compound 3 was reacted with electro-hilic reagents (bromine, phenyldiazonium chloride, nitrous acid, a Vielsmeier-Haack reagent, aromatic aldehydes and diethyl oxalate) to yield 1-substituted-3,4-dihydro[1H,6H)-1,4-oxazino[3,4-

  通过不同的途径制备了3，4-二氢-1 H，6 H- [1，4]恶嗪基[3，4- b ]喹唑啉-6-one 3及其1-甲基和1-羟基衍生物8和13。使化合物3的活性亚甲基与电子-羟基试剂（溴，氯化苯基重氮，亚硝酸，Vielsmeier-Haack试剂，芳族醛和草酸二乙酯）反应，生成1-取代的3,4-二氢[1 H， 6 H）-1,4-恶嗪基[3,4- b ]喹唑啉-6-酮。1-羟基和1-溴衍生物13和15的反应性在某些反应中也进行了调查。通过uv，1 H和13 C nmr光谱对3,4-二氢-1 H，6 H- [1,4]恶嗪基[3,4- b ]喹唑啉-6-进行了表征。
• Ruthenium(II) complexes with 2-methyl-3-substituted (3H)-quinazolin-4-ones
  作者：K.Laxma Reddy、P. Lingaiah、K.Veera Reddy

  DOI：10.1016/s0277-5387(00)84550-7

  日期：1986.1

  complexes of some polydentate ON, OO and ONO donors in the form of 2-methyl-3-substituted (3H)-quinazolin-4-ones have been synthesized and studied. The reaction between RuCl2(DMSO)4 and the uninegative bidentate ligands yielded complexes of the type Ru(DMSO)2(OO)2 (OO = MHQ, PHQ, MHEQ, MHPQ or MCMQ), displacing only two DMSO groups along with chlorides, whereas the neutral bidentate ligands gave

  合成了一些多齿ON，OO和ONO供体的钌（II）配合物，它们以2-甲基-3-取代的（3 H）-喹唑啉-4-酮的形式存在，并且研究过。RuCl 2（DMSO）4与非负二齿配体之间的反应产生Ru（DMSO）2（OO）2类型的配合物（OO= MHQ，PHQ，MHEQ，MHPQ或MCMQ），仅取代了两个DMSO基团以及氯化物，而中性双齿配体给出RuCl 2（ON）2（ON= MAQ，PAQ，MANQ，PANQ，MAAQ，MAPQ，MPQ或PPQ），取代了所有DMSO基团。然而，具有O = N = O供体的单负性齿状配体（MHAQ）生成了钌（II）的双螯合物。